| Literature DB >> 36158150 |
Titus Andrian1,2, Etienne Novel-Catin1, Claire Triffault-Fillit3, Maud Rabeyrin4, Christophe Barba1, Laetitia Koppe1, Denis Fouque1.
Abstract
Entities:
Year: 2022 PMID: 36158150 PMCID: PMC9494545 DOI: 10.1093/ckj/sfac117
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Laboratory tests
| Creatinine (μmol/L) | 346 μmol/L |
| eGFR CKD-EPI 2021 (mL/min/1.73 m2) | 15 mL/min/1.73 m2 |
| Proteinuria (g/24 h) | 1.8 g/24 h |
| Haematuria (RBC per HPF) | 45 |
| Haemoglobin | 7.9 g/dL |
| HIV, hepatitis C, hepatitis B serologies | Negative |
| Complement factor 3 (g/L) | 0.7 g/L |
| Anti-nuclear antibody | Negative |
| Anti-double stranded DNA | Negative |
| Anti-glomerular basement membrane | Negative |
| Anti-neutrophil cytoplasmic antibody (ANCA) MPO | Negative |
| Anti-neutrophil cytoplasmic antibody (ANCA) PR3[ | Positive |
| Cryoglobulin | Positive (mixed) |
ANCA PR-3 were determined by immunofluorescence testing and flow flurometry (Biorad reactive). CKD-EPI, Chronic kidney disease epidemiology collaboration; RBC, red blood cells; HPF, high-power field.
FIGURE 1:Kidney biopsy. (A) C4d deposits on immunofluorescence (IF). (B) C3 deposits on IF. (C) C1q deposits on IF. (D) Masson-Trichrome staining, ×400. Mesangial and endocapillary proliferation with cellular crescent and fibrinoid necrosis.